Key result
Antisense oligonucleotide selection scheme targets DMD exon 16 skipping for rare Duchenne muscular dystrophy mutations.
Why the study?
Approved antisense oligonucleotide therapies for Duchenne muscular dystrophy only apply to 27% of patients, leaving most individuals with rare mutations without therapeutic options.
Comparison
A 59-member library of tricyclo-DNA antisense oligonucleotides targeting DMD exon 16
Design
Preclinical methodology and proof-of-concept screening study
Answers are grounded in this paper and cite their sources.
Expands exon skipping options for rare DMD mutations; leaves open clinical translation and validation.
Over the last decades, antisense oligonucleotides (AONs) have emerged as powerful tools to modulate alternative splicing, allowing exclusion of a specific exon from a target mRNA to bypass mutations or restore the reading frame, enabling production of a functional protein. In Duchenne muscular dystrophy (DMD), a lethal X-linked disorder affecting 1:5,000 males, four AON therapies have received accelerated approval. However, these treatments are applicable to only 27% of patients, leaving most individuals with rare mutations without therapeutic options. Here, we outline a methodology to identify relevant AONs for such populations. This approach aims to prequalify candidates and eliminate unsuitable leads before animal testing, reducing development time and costs. Following high-throughput screening, selected AONs are assessed for intravenous delivery compatibility and serum protein binding to support model selection and forecast human pharmacokinetics. As proof of concept, we applied this strategy to tricyclo-DNA AONs targeting an ultra-rare DMD exon 16 mutation. From a 59-member library, we defined a lead compound with efficient exon 16 skipping, favorable pharmacokinetic and safety profiles, able to rescue dystrophic transcriptomic and proteomic signatures. This study demonstrates the feasibility of developing a safe and effective lead compound within a reasonable time frame and cost, supporting compassionate use and future n = 1 trials.
No takes yet. Share an insight, caveat, or question.
Geoffroy-Guiraud et al. (2026) studied this question. An antisense oligonucleotide selection scheme was applied to DMD exon 16 skipping for the treatment of rare Duchenne muscular dystrophy mutations.
Synapse has enriched 10 related papers. Consider them for comparative context: